Inclusion Criteria:
  -  Controlled intermittent asthma (step 1 treatment, according to GINA Guideline 2016) with or without association with cat allergy related rhino-conjunctivitis;
  -  Sensitization to cat allergen extract as defined by skin prick test for cat extract with a wheal diameter of ≥3 mm greater than negative control (ALK, HØrsholm, Denmark) and specific IgE anti Fel d 1 ≥ 0.7 kU/L ( ImmunoCAP, Thermofisher, Uppsala, Sweden);
  -  FEV1 ≥ 70% of the predicted value;
  -  No cat exposure at home or outside of the home during the study;
  -  Positive methacholine challenge test performed using an AeroDoseur DTF-Atomisor ATO-AD 12 (Saint-Etienne, France);     
  -  Early asthmatic response during baseline cat allergen exposure.
Exclusion Criteria:
  -  Uncontrolled asthma, asthma control test inferior to 20 within the 4 weeks preceding the study.
  -  Uncontrolled asthma 2 weeks after stopping LABA treatment.
  -  LABA treatment within the 2 weeks preceding the study.
  -  Severe asthma (> GINA 2)
  -  Subject lives with a cat
  -  Cat desensibilisation within the 6 previous months.
  -  Active smoker
